# XOMA Royalty to Present at Investor Conferences in March Canonical URL: https://biopharmsignal.com/news/XOMA/xoma-royalty-to-present-at-investor-conferences-in-march Ticker: XOMA Company: XOMA Corporation Source: XOMA Corporation Published: 2026-02-18 21:30 EST Original Source URL: https://investors.xoma.com ## Summary

EMERYVILLE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March. Management will also participate in one-on-one investor meeting ## Article Body EMERYVILLE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March.  Management will also participate in one-on-one investor meetings. T.D. Cowen 46th Annual Health Care Conference (March 2-4, 2026) Format: Fireside chat Date: Monday, March 2, 2026 Time: 11:50AM ET Location: Boston, MA Link: https://bit.ly/3JXiyRJ Leerink 2026 Global Healthcare Conference (March 8-11, 2026) Format: Fireside chat Date: Wednesday, March 11, 2026 Time: 11:20AM ET Location: Miami Beach, FL Link: https://bit.ly/499Y0Og XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  A replay of each presentation will be available and archived on the site for 90 days after the event. About XOMA Royalty Corporation XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn. XOMA Investor Contact XOMA Media Contact Juliane Snowden Kathy Vincent XOMA Royalty  KV Consulting & Management +1 646-438-9754 kathy@kathyvincent.com juliane.snowden@xoma.com Source: XOMA Royalty Corporation ## Recent Company News - 2026-07-14 13:00 EST — [XOMA Royalty Announces Closing of Its Acquisition by Ligand](https://biopharmsignal.com/news/XOMA/xoma-royalty-announces-closing-of-its-acquisition-by-ligand-6ca7a63d) — Source: XOMA Corporation - 2026-06-12 20:05 EST — [XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date](https://biopharmsignal.com/news/XOMA/xoma-royalty-corporation-declares-quarterly-preferred-stock-dividend-and-announc-b8285e5a) — Source: XOMA Corporation - 2026-04-27 11:00 EST — [Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator](https://biopharmsignal.com/news/XOMA/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligand-s-position-as-a-leading-biopharma-royalty-aggregator) — Source: XOMA Corporation - 2026-03-18 20:30 EST — [XOMA Royalty Declares Quarterly Preferred Stock Dividends](https://biopharmsignal.com/news/XOMA/xoma-royalty-declares-quarterly-preferred-stock-dividends) — Source: XOMA Corporation - 2026-03-18 10:00 EST — [XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements](https://biopharmsignal.com/news/XOMA/xoma-royalty-reports-2025-financial-results-and-highlights-recent-business-achievements) — Source: XOMA Corporation ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)